DEFIANCE TRILLION DC IDX ETF (TRIL) Stock Price, Forecast & Analysis

What does DEFIANCE TRILLION DC IDX ETF do?

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. The company is headquartered in Mississauga, Ontario and currently employs 33 full-time employees. The company went IPO on 2005-01-11. The firm is engaged in developing therapies for the treatment of cancer. The firm is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). The company focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

What is the stock price of DEFIANCE TRILLION DC IDX ETF today?

The current stock price of TRIL is 20.48 USD. The price increased by 0.44% in the last trading session.

How is the ChartMill rating for DEFIANCE TRILLION DC IDX ETF?

TRIL has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.

Which stock exchange lists TRIL stock?

TRIL stock is listed on the Nasdaq exchange.